Cordycepin, scientifically known as 3'-deoxyadenosine, is a naturally occurring nucleoside analogue first isolated by Cunningham in 1951. Initially identified as an antibacterial compound from Cordyceps militaris—a species of ascomycete fungus that parasitizes soil-dwelling caterpillars—it has since emerged as a research hotspot due to its diverse biological activities.
Beyond its primary name, cordycepin is recognized by several synonyms in scientific and industrial contexts, including 9-cordyceposido adenosine, adenine coryceposide, cordycepine, NSC 401022, and NSC 63984, with a CAS registration number of 73-03-0. Its molecular structure closely resembles that of adenosine, the key difference being the absence of a 3' hydroxyl group—a feature that underpins its unique biological mechanisms.
Notably, Cordyceps militaris stands out as the only strain among over 500 Cordyceps species capable of producing cordycepin in substantial quantities. Modern advancements in cultivation techniques have enabled scalable production of cordycepin, moving beyond reliance on wild fungal sources and supporting its application across multiple industries. Since the 1990s, it has entered clinical trial phases (starting with Phase I trials in the United States in 1997) and continues to be explored for its therapeutic potential.
Cordycepin